Addex Therapeutics Ltd. — 6-K Filing

Routine SEC filing; no new financial or operational data disclosed.

What the company is saying

Addex Therapeutics Ltd has filed a Form 6-K with the SEC for September 2026, serving primarily as a procedural update. The filing attaches a press release dated September 25, 2026, as Exhibit 99.1 and formally incorporates it into the company's registration statements on Form F-3 (No. 333-291644) and Form S-8 (Nos. 333-255124 and 333-272515). The company explicitly highlights that its business faces significant risks and directs investors to its Annual Report on Form 20-F for the year ended December 31, 2025, filed May 15, 2026, for detailed risk factors. The language is neutral and legalistic, emphasizing forward-looking statements and the potential for actual results to differ materially from expectations. No operational, financial, or clinical results are presented in this filing. The only named executive is Tim Dyer, Chief Executive Officer, who signed the report on September 25, 2026.

What the data suggests

The filing is administrative, with no new numbers or operational milestones. It references the incorporation of a press release into multiple registration statements, listing their exact SEC registration numbers. The only dated events are the press release and report signature, both on September 25, 2026. The company reiterates that its business, financial condition, results of operations, and growth prospects are subject to significant risks, but provides no quantification or specific examples within this document. There are no disclosed financial figures, clinical data, or project updates. The only actionable facts are the legal and procedural steps taken to update SEC records and the reaffirmation of risk disclosures.

Analysis

The announcement is a routine regulatory filing (Form 6-K) that serves primarily to incorporate a press release and reference existing registration statements and risk factors. There are no operational, financial, or clinical results disclosed, nor are there any claims of realised or imminent business milestones. The language is factual and procedural, with explicit caution regarding forward-looking statements and risks, rather than promotional or exaggerated. No capital outlay or project investment is mentioned, and there is no discussion of timelines for any business benefits. The only forward-looking content is the standard legal disclaimer about risks and uncertainties, which is proportionate and required by regulation. There is no gap between narrative and evidence, as no positive narrative is advanced.

Risk flags

• ●The filing highlights that Addex Therapeutics Ltd's business faces significant risks, referencing risk factors in its Annual Report on Form 20-F for the year ended December 31, 2025. This signals ongoing exposure to operational, financial, or regulatory uncertainties that could materially affect the company.
• ●The document contains forward-looking statements and cautions that actual results may differ materially from expectations due to these risks. This standard legal disclaimer underscores uncertainty and the absence of new mitigating information in this update.
• ●No new financial or operational data are disclosed, leaving investors reliant on previously filed documents for current business status. This limits transparency and the ability to assess near-term performance or risk mitigation progress.

Bottom line

This Form 6-K filing by Addex Therapeutics Ltd is a routine regulatory update, serving to incorporate a recent press release into existing SEC registration statements. No new financial, operational, or clinical information is disclosed, and the filing consists mainly of legal and risk-related language. Investors receive a reminder of significant business risks and are directed to previously filed annual reports for substantive details. The only concrete facts are procedural: the attachment of Exhibit 99.1 and the reaffirmation of risk factors. There is no actionable update or new insight into the company's trajectory in this announcement; investors must look to future filings or referenced documents for material developments.

Announcement summary

(NASDAQ:ADXN) Addex Therapeutics Ltd filed a Form 6-K with the United States Securities and Exchange Commission for the month of September 2026. The filing includes a press release dated September 25, 2026, which is attached as Exhibit 99.1 and incorporated by reference. Exhibit 99.1 is also incorporated by reference into the registration statement on Form F-3 (Registration No. 333-291644) and the registration statements on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd. The company states that its business faces significant risks, and refers investors to the risk factors set forth in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026. The report notes that the business, financial condition, results of operations, and growth prospects could be materially adversely affected by these risks. The filing contains forward-looking statements that involve risks and uncertainties. The company cautions that actual results could materially differ from those anticipated in the forward-looking statements due to certain factors, including the risks described in its Annual Report and other SEC filings. The report is signed on behalf of Addex Therapeutics Ltd by Tim Dyer, Chief Executive Officer, on September 25, 2026. The principal executive office is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland. The company indicates that it files annual reports under cover of Form 20-F. The Commission File Number for this filing is 001-39179. The report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The press release attached as Exhibit 99.1 is deemed to be a part of the registration statements from the date of filing, unless superseded by later documents.

Disagree with this article?